Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor)
BOSTON, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Carrick Therapeutics Inc., an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating CT7439, a novel cyclin dependent kinase 12/13 (CDK12/13) inhibitor / Cyclin-K glue-degrader. CDK12/13 is implicated in multiple cancer types, as they regulate transcription elongation, RNA splicing, as well as cleavage and polyadenylation. DNA damage response genes are particularly suppressed by loss of CDK12/13 activity. The clinical trial is enrolling patients with advanced solid tumors, including ovarian, breast and Ewing's Sarcoma.
"Initiation of our CT7439 Phase 1 clinical trial marks the advancement of our second therapeutic into the clinic for aggressive and resistant forms of cancer,” said Tim Pearson, Chief Executive Officer of Carrick Therapeutics. “CT7439 is the first CDK12/13 inhibitor to enter clinical development, and we are encouraged by its potential as monotherapy or combination therapy across multiple tumor types.”
The Phase 1 clinical trial is a modular design, beginning with a dose escalation for the initial administration of CT7439 to patients. The initial clinical evaluation will be focused on safety and pharmacokinetics, with an opportunity for early Proof of Principle using a blood based pharmacodynamic assay of the homologous recombination repair (HRR) pathway.
Clinical trial details can also be found on www.clinicaltrials.gov under study ID: NCT06600789. For additional information on the clinical trial, please contact hello@carricktherapeutics.com.
About CT7439
CT7439 is an inhibitor of CDK12/13 as well as a 'glue degrader' of Cyclin-K, which is the obligate co-factor for CDK12/13, giving both first-in-class and best-in-class potential. This dual modality significantly increases the potency of the compound and leads to the inhibition of DNA repair at the transcriptional level. CDK12/13 regulates gene transcription through the activation of RNA Polymerase II. It has the potential to synergise with other agents targeting DDR such as the PARP inhibitors in multiple cancer types, including breast, ovarian and Ewing’s Sarcoma.
About Carrick Therapeutics
Carrick Therapeutics is an oncology-focused biopharmaceutical company developing highly differentiated novel therapies that address significant unmet needs. The Company’s lead program, samuraciclib, is a novel oral first-in-class inhibitor of CDK7 currently in multiple Phase 2 clinical trials for metastatic HR+ breast cancer. The Company is collaborating with Roche, Menarini Group and Arvinas/Pfizer to evaluate novel combinations of samuraciclib with oral SERD endocrine therapies. Additionally, Carrick is developing CT7439, a novel CDK12/13 inhibitor / Cyclin-K glue-degrader, which is currently in a Phase 1 clinical trial.
For more information about Carrick Therapeutics, please visit www.carricktherapeutics.com
Carrick Contact
Carrick Therapeutics
Jenny Horsfield, Chief Business Officer
jenny.horsfield@carricktherapeutics.com
Investors and Media
Luke Heagle, Real Chemistry
lheagle@realchemistry.com
Released September 23, 2024